MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.14

-0.1%

10:04 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (2195)	7/8/2009 7:35:53 PM
From: Pseudo Biologist	Read Replies (1) of 2240

My recollection is that denosumab was an Amgen project using ABGX technology - very much unlike Vectibix, which was an internal Abgenix project later partnered with Immunex (from memory, not double checking). I see deno closer to a "cash-and-carry" to used Medarex terminology. If ABGX had stayed independent deno would represent a nice royalty stream but far from the full value of the project. If I am correct with my history on the origin of this project, it is an exaggeration to say that in one morning it [Abgenix] has added $9bn to AMGN's value Back in the days of the acquisition, some said that eliminating the potential royalty obligation to ABGX helped justify the price AMGN paid for it - this I can buy. I tend to agree with Iceberg here. From edgar.brand.edgar-online.com (10Q June 2004) In addition to our proprietary antibody therapeutic product candidates in clinical trials, there are four customer-developed antibodies generated with XenoMouse technology in clinical trials as follows: • Pfizer Inc.—We generated three XenoMouse-derived fully human antibody therapeutic product candidates that Pfizer has advanced into clinical trials, including one that targets cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and one that targets activated type 1 insulin-like growth factor receptors (IGF-1R). Two of the product candidates are currently in phase 1 evaluation and one has advanced to phase 2 evaluation. • Amgen—We generated a XenoMouse-derived fully human antibody therapeutic product candidate that binds to the receptor activator of nuclear factor kappa B ligand (RANKL) that Amgen has advanced into clinical trials as AMG162 as a potential treatment for bone loss. AMG162 = anti-RANKL or denosumab

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next